Conferences - Results from #540

Viewing 541-560 of 11745 articles

AUA 2024: First Results of NURE-Combo: A Phase 2 Study of Neoadjuvant Nivolumab and Nab-Paclitaxel Followed by Postsurgical Adjuvant NIVO in Patients with Muscle-Invasive Bladder Cancer

AUA 2024: Panel Discussion: Artificial Intelligence

AUA 2024: Outcomes of Minimally Invasive Nephrectomy Following Immune-Checkpoint Inhibitor Therapy: Data from a Multicenter Study

AUA 2024: Panel Discussion: Obstructive Pyelonephritis Due to Ureteral Stone

AUA 2024: Response to Primary Chemoablation With UGN-102 in Patients with New or Recurrent LG IR NMIBC: Post-hoc Analysis of the ATLAS Trial

AUA 2024: Genomic Signatures Associated with Adverse Pathologic Features at Radical Prostatectomy Among Active Surveillance Eligible Men

AUA 2024: High Decipher® Score Defines the Subgroup Most at Risk of Metastatic Progression Among Patients with Lower Grade Tumors Classified as NCCN High-Risk Based on Elevated Prostate-Specific Antigen Level Alone

AUA 2024: Comparing Methocarbamol to Oxybutynin for Stent Colic – A Prospective Randomized Controlled Trial

AUA 2024: First Prospective Clinical Assessment of The ILY Robotic Flexible Ureteroscopy Platform.

AUA 2024: Automated Renal Volume Measurement using Artificial Intelligence: Correlation to Post-Operative Renal Function after Radical and Partial Nephrectomy

AUA 2024: Journal of Urology Lecture: Empowering Communities: Fostering Prostate Cancer Awareness and Resilience Among Men of Color

AUA 2024: Development and External Validation of an Artificial Intelligence-Based Tool for PROGression Risk Assessment in Non-Muscle Invasive Bladder Cancer (PROGRxN-BCa)

AUA 2024: Comprehensive Evaluation of Response to Immune Checkpoint Blockade in Primary Tumor: Radiographic and Radiomic Features Predict Pathologic Response in Primary Tumor

AUA 2024: Efficacy and Safety of Padeliporfin Vascular Targeted Photodynamic Therapy (VTP) for Treatment of Low-Grade Upper Tract Urothelial Cancer (LG UTUC): Phase 3 Preliminary Results

AUA 2024: Computer Vision Analysis of Upper Tract Urothelial Carcinoma to Predict High vs Low Grade Pathology

AUA 2024: Development and Validation of Generalizable Interpretable AI Biomarkers to Predict Clinical Outcomes in BCG-Treated Patients with Non-Muscle Invasive Bladder Cancer

AUA 2024: Survival is Dramatically Improved for mRCC Patients with Sarcomatoid Features who are Treated with Cytoreductive Nephrectomy and Immune Checkpoint Inhibitors Regardless of Treatment Sequence

AUA 2024: Tumor Size Reduction (≥10% ) Resulting from Pre-Surgical Systemic Therapy Predicts Improved Survival Following Cytoreductive Nephrectomy

AUA 2024: Predicting Response to Intravesical BCG in High Risk Non-Muscle Invasive Bladder Cancer Using an Artificial Intelligence-Powered Pathology Assay: Development and Validation in an International 12 Center Cohort

AUA 2024: State-of-the-Art Lecture: Advances in Molecular Imaging for Renal Tumors

23
24
25
26
27
28
29
30
31
32